Latest Cryosite News

Cryosite delivered record first-quarter results, with revenue up 17% to $4.6 million and EBITDA rising 31% to $1.3 million. The more consequential test now sits with the TGA, which has audited the company’s Auburn facility as part of a potential licence expansion.

Cryosite Limited delivered robust FY26 results with revenue up 18% to $16.7 million and net profit rising 19%, underpinned by a strategic warehouse acquisition that doubled storage capacity and a cool room expansion.

Cryosite Limited reported an 18% rise in FY2026 revenue to $16.7 million, with EBITDA growing 27% amid completed and ongoing facility expansions. The company aims to convert new capacity into client growth in FY2027.

Cryosite Limited delivered a robust 22% revenue increase and 28% EBITDA growth for the ten months to April 2026, powered by expanding clinical trial activity and infrastructure upgrades.

Cryosite Limited reported a robust half-year with revenue up 25% and net profit rising 36%, driven by strong demand in temperature-controlled logistics and a strategic warehouse acquisition that doubles its storage capacity.

Cryosite Limited reports a strong start to FY26 with a 22% revenue increase and a strategic warehouse acquisition that doubles capacity, positioning the company for sustained growth in clinical trial logistics.

Cryosite Limited has inked a deal to acquire a strategic freehold warehouse in Auburn, NSW, doubling its storage capacity and positioning itself for significant growth in clinical trial logistics.

Cryosite Limited reported a 12% increase in revenue for FY25, driven by a 58% surge in its ultra-frozen and cryogenic segment, while deferring dividends to fund expansion plans.